Double Down for a Double Win

[摘要]：The rationale for using multiple inhibitors between and within the phosphoinositide 3-kinase/AKT/mTOR and RAS/MEK/ERK pathways is scientifically compelling, and a limited number of experimental agents are currently being tested in phase I combinations. Patient subpopulations, whose tumors are defined by genetic lesions, are showing promising responses to this approach. Clin Cancer Res; 18(8); 2124-6. (C) 2012 AACR.

[全文传递流程]：

一般上传文献全文的时限在1个工作日内